Sihuan Pharmaceutical (0460.HK): Sunshine Life Insurance Leads Investment in Xuanzhu Biopharm - PR Newswire APAC
Summary
The participation of heavy-weighted strategic investors in both rounds fully demonstrates Xuanzhu Biopharms unceasing innovation capabilities and the forward-looking layout of Sihuan Pharmaceutical which the capital market has recognized. At the same time, we will gradually expand the comprehensive strength encompassing overseas collaboration, industrialization and commercialization, and create a novel, innovative pipeline and portfolio that is differentiated and sustainable. For nearly ten years of establishment and development, Xuanzhu Biopharm has assembled an outstanding team of almost 400 members, led by oversea returnee scientists, with independent R&D capabilities of innovative drugs. For more information on Sihuan Pharmaceutical, please visit the company website https://www.sihuanpharm.com/ Sunshine Life Insurance Corporation Limited was established on December 17, 2007 with a registered capital of RMB18.3425 billion. At present, the company has established 33 secondary institutions and nearly 1,000 third- and fourth-level branches to provide customers with life, pension, medical, health, accident and other insurance protection with professional services.